Skip to main content

Table 1 Cumulative incidence and mean scores of arthritis in mice treated with wild-type or IFN-γR KO DBA/1 MSCs or with C57BL/6 MSCsa

From: Discrepancy between the in vitro and in vivoeffects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis

Experiment Routeb Administration timec Treatmentd Cumulative incidencee, fraction (percentage) Score of arthritis, mean ± SEMe, f
1 i.v. Day -1 Control 4/8 (50%) 2.0 ± 0.9
    Wild-type MSCs 1/2 (50%) 1.5 ± 1.5
    IFN-γR KO MSCs 3/7 (43%) 1.6 ± 1.0
    Treg cells 2/8 (25%) 0.4 ± 0.3
2 i.v. Day 16 Control 4/10 (40%) 1.3 ± 0.7
    Wild-type MSCs 6/8 (75%) 2.1 ± 0.6
    IFN-γR KO MSCs 4/10 (40%) 0.8 ± 0.4
3 i.v. Days 16 and 23 Control 5/10 (50%) 3.0 ± 1.4
    Wild-type MSCs 5/9 (56%) 2.5 ± 0.9
    IFN-γR KO MSCs 5/10 (50%) 2.0 ± 0.8
4 i.p. Days 16, 23, and 30 Control 7/8 (88%) 5.1 ± 1.5
    Wild-type MSCs 6/7 (86%) 5.3 ± 1.2
    IFN-γR KO MSCs 8/9 (89%) 4.6 ± 1.6
5 i.p. Days 16, 23, and 30 Control 7/11 (64%) 1.3 ± 0.5
    C57BL/6 MSCs 8/11 (73%) 2.7 ± 1.2
  1. aMice were immunized with collagen type II in complete Freund's adjuvant on day 0 and were treatedb either intravenously (i.v.) or intraperitoneally (i.p.) on the indicated time pointsc with wild-type mesenchymal stem cells (MSCs), interferon-gamma receptor knockout (IFN-γR KO) MSCs, C57BL/6 MSCs, regulatory T (Treg) cells, or phosphate-buffered saline (control group)d. eArthritic incidence and score of arthritis in all groups at day 35. fArthritic scores were not significantly different between control treatment and treatment with wild-type or IFN-γR KO DBA/1 MSCs or C57BL/6 MSCs or with Treg cells. SEM, standard error of the mean.